Serina Therapeutics (SER) CFO awarded 123,019 stock options at $1.89

Rhea-AI Filing Summary

Serina Therapeutics, Inc. reported that Chief Financial Officer Gregory S. Curhan received a compensation grant of stock options covering 123,019 shares of common stock at an exercise price of $1.89 per share. The options vest over four years, with 12/48ths vesting one year after the Vesting Commencement Date and 1/48th each month thereafter, and expire on May 21, 2036. Following this award, Curhan holds stock options for 123,019 underlying shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CURHAN GREGORY S

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	123,019	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 123,019 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 123,019 shares Exercise price: $1.89 per share Expiration date: May 21, 2036 +3 more

6 metrics

Option grant size 123,019 shares Underlying common stock in CFO stock option award

Exercise price $1.89 per share Strike price of CFO stock option grant

Expiration date May 21, 2036 Option term end date for CFO grant

Post-grant option holdings 123,019 options Total stock options held directly after this award

Initial vesting tranche 12/48ths of shares Vest twelve months after Vesting Commencement Date

Ongoing vesting rate 1/48th per month Monthly vesting after initial twelve-month cliff

Key Terms

Stock Option (right to buy), exercise price, Vesting Commencement Date, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "1.8900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Vesting Commencement Date financial

"twelve months after the Vesting Commencement Date, and 1/48th"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

vesting financial

"shares subject to the option shall vest twelve months after"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-05-21T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CURHAN GREGORY S

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE ALABAMA 35806

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.89	05/21/2026		A		123,019		(1)	05/21/2036	Common Stock	123,019	$0	123,019	D

Explanation of Responses:

1. Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.

Remarks:

	/s/ Gregory S. Curhan	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Serina Therapeutics (SER) disclose for its CFO?

Serina Therapeutics disclosed that CFO Gregory S. Curhan received a grant of stock options for 123,019 shares of common stock. These options are a compensation award, not an open-market purchase, and give the right to buy shares at a fixed exercise price.

How many Serina Therapeutics (SER) shares are covered by the CFO’s new stock options?

The new stock option grant covers 123,019 shares of Serina Therapeutics common stock. This number reflects the underlying shares tied to the option award reported, all held directly by the Chief Financial Officer after this transaction.

What is the exercise price of the Serina Therapeutics CFO’s stock option grant?

The stock options granted to the Serina Therapeutics CFO have an exercise price of $1.89 per share. This means he can purchase up to 123,019 shares at $1.89, regardless of the market price, once the options are vested and exercisable.

How do the Serina Therapeutics CFO’s stock options vest over time?

The options vest over four years, with 12/48ths of the shares vesting twelve months after the Vesting Commencement Date. The remaining 1/48th of the shares vest on the same calendar day of each subsequent month until fully vested, assuming continued service.

When do the Serina Therapeutics CFO’s newly granted stock options expire?

The stock options granted to the Serina Therapeutics CFO expire on May 21, 2036. If not exercised by that expiration date, the right to buy the 123,019 underlying shares at $1.89 per share will lapse under the option’s terms.

Is the Serina Therapeutics CFO’s Form 4 transaction a stock purchase or a grant?

The Form 4 shows a grant or award acquisition of stock options, not an open-market stock purchase. The CFO received options to buy 123,019 shares at $1.89 per share as part of compensation, subject to the specified vesting schedule and expiration date.